Relevant bibliographies by topics / Antiobesity effects / Journal articles

Journal articles on the topic 'Antiobesity effects'

To see the other types of publications on this topic, follow the link: Antiobesity effects.
Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Antiobesity effects.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Mark, Allyn L. "Cardiovascular Side Effects of Antiobesity Drugs." Circulation 120, no. 9 (September 2009): 719–21. http://dx.doi.org/10.1161/circulationaha.109.888529.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Shiffman, Melvin A. "Anesthesia Risks in Patients Who Have Had Antiobesity Medication." American Journal of Cosmetic Surgery 15, no. 1 (March 1998): 3–5. http://dx.doi.org/10.1177/074880689801500102.

Full text
Abstract:
The effects of antiobesity medication can include cardiac valvular disorders and pulmonary hypertension. Fenfluramine, phentermine, and dexfenfluramine are particularly prone to cause these problems. Sudden hypotension with administration of general anesthesia in patients who have taken antiobesity drugs has been reported. The cosmetic surgeon should question patients regarding intake of antiobesity medications and should consider cardiac workup prior to performing surgery.
APA, Harvard, Vancouver, ISO, and other styles
3

Fernández-Galilea, Marta, Pedro L. Prieto-Hontoria, J. Alfredo Martínez, and María J. Moreno-Aliaga. "Antiobesity effects of α-lipoic acid supplementation." Clinical Lipidology 8, no. 3 (June 2013): 371–83. http://dx.doi.org/10.2217/clp.13.19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hwang, Jin Taek, Sanghee Kim, Bo-ra Yoon, Inwook Choi, and Sang Yoon Choi. "Inhibitory Effects of 4-(4-Methylbenzamino)benzoate on Adipocyte Differentiation." Journal of Chemistry 2015 (2015): 1–4. http://dx.doi.org/10.1155/2015/171570.

Full text
Abstract:
The potent suppression of adipocyte differentiation by 4-(4-methylbenzamino)benzoate was discovered during the search for new antiobesity compounds. 4-(4-methylbenzamino)benzoate was observed to suppress adipocyte differentiation in 3T3-L1 cells by 96.8% at 50 μM without cytotoxicity. In addition, 4-(4-methylbenzamino)benzoate reduced the cellular expression of fatty acid synthase in a concentration-dependent manner, as well as suppressing PPAR-gamma activity, which controls fatty acid storage and glucose metabolism. Based on these results, 4-(4-methylbenzamino)benzoate shows potential as an antiobesity material.
APA, Harvard, Vancouver, ISO, and other styles
5

Cheng, Lizeng, Yang Wei, Lurong Xu, Lanlan Peng, Yuanfeng Wang, and Xinlin Wei. "Gut Microbiota Differentially Mediated by Qingmao Tea and Qingzhuan Tea Alleviated High-Fat-Induced Obesity and Associated Metabolic Disorders: The Impact of Microbial Fermentation." Foods 11, no. 20 (October 14, 2022): 3210. http://dx.doi.org/10.3390/foods11203210.

Full text
Abstract:
Although dark tea is a unique microbial-fermented tea with a high reputation for having an antiobesity effect, little is known about the effect of microbial fermentation on tea leaves’ antiobesity properties. This study compared the antiobesity effects of microbial-fermented Qingzhuan tea (QZT) and unfermented Qingmao tea (QMT), providing insight into their underlying mechanisms associated with gut microbiota. Our results indicated that the supplementation of QMT extract (QMTe) and QZT extract (QZTe) displayed similar antiobesity effects in high-fat diet (HFD)-fed mice, but the hypolipidemic effect of QZTe was significantly stronger than that of QMTe. The microbiomic analysis indicated that QZTe was more effective than QMTe at regulating HFD-caused gut microbiota dysbiosis. Akkermansiaceae and Bifidobacteriaceae, which have negative correlations with obesity, were enhanced notably by QZTe, whereas Faecalibaculum and Erysipelotrichaceae, which are positively correlated with obesity, were decreased dramatically by QMTe and QZTe. A Tax4Fun analysis of QMTe/QZTe-mediated gut microbiota revealed that QMTe supplementation drastically reversed the HFD-induced upregulation of glycolysis and energy metabolism, whereas QZTe supplementation significantly restored the HFD-caused downregulation of pyruvate metabolism. Our findings suggested that microbial fermentation showed a limited effect on tea leaves’ antiobesity, but enhanced their hypolipidemic activity, and QZT could attenuate obesity and associated metabolic disorders by favorably modulating gut microbiota.
APA, Harvard, Vancouver, ISO, and other styles
6

Debellis, Lindsay R., and Mark J. Wrobel. "Pharmacotherapeutic Options for the Treatment of Patients with Obesity." Journal of Pharmacy Technology 28, no. 5 (September 2012): 211–18. http://dx.doi.org/10.1177/875512251202800508.

Full text
Abstract:
Objective: To assess the safety and efficacy of FDA-approved and in-development antiobesity agents. Data Sources: Literature was accessed through MEDLINE (1950-current) and EMBASE using the terms antiobesity agent, diethylpropion, phentermine, orlistat, topiramate, lorcaserin, bupropion, and naltrexone. In addition, reference citations from publications identified were reviewed. Files related to FDA expert panel hearings were retrieved from the FDA website. Study Selection and Data Extraction: Randomized double-blind trials assessing the efficacy and safety of antiobesity agents compared with placebo in the treatment of overweight and obese adults were reviewed. Only English-language or English-translated literature was reviewed. Medications were selected based on FDA approval status. Data Synthesis: Ten double-blind clinical trials were reviewed. There are currently 5 FDA-approved antiobesity agents and 1 agent recently rejected by the FDA. Study results for all agents showed statistically significant weight loss compared with placebo, but with varying adverse effects. The combination of phentermine and topiramate is the most efficacious antiobesity agent approved by the FDA. However, this combination has various neurologic, cardiovascular, and teratogenic safety risks that may limit its use. Based on its safety profile, orlistat is the preferred antiobesity medication, despite the lesser extent to which it induces weight loss versus newer agents. The incidence of unwanted gastrointestinal adverse effects limits its use. Conclusions: Despite a glaring medical need for options to treat obesity, available medications are limited. No current drug option is ideal; each has either safety risks or efficacy concerns. Safe agents that meet FDA efficacy standards are needed to help treat the obesity epidemic.
APA, Harvard, Vancouver, ISO, and other styles
7

Antunes, Kátia Avila, Débora da Silva Baldivia, Paola dos Santos da Rocha, Junior Cesar Casagrande, Eliana Janet Sanjinez Argandoña, Maria do Carmo Vieira, Cláudia Andrea Lima Cardoso, Edson Lucas dos Santos, and Kely de Picoli Souza. "Antiobesity Effects of Hydroethanolic Extract of Jacaranda decurrens Leaves." Evidence-Based Complementary and Alternative Medicine 2016 (2016): 1–8. http://dx.doi.org/10.1155/2016/4353604.

Full text
Abstract:
Obesity is a worldwide epidemic that reduces life expectancy; therefore, the search for new alternative and effective treatments is ongoing. The aim of the present investigation was to identify the chemical compounds in the hydroethanolic extract of leaves of Jacaranda decurrens subsp. symmetrifoliolata and to evaluate their toxicity and antiobesity effects. High-performance liquid chromatography was used to identify the chemical constituents, and acute toxicity was evaluated in rats treated with doses of 2 and 5 g·kg−1 body mass. The antiobesity effect was determined in rats with hypercaloric diet-induced obesity. Our results revealed the presence of compounds, such as jacaric, ursolic, and oleic acids, as well as luteolin, quercetin, and kaempferol, in the extract. The acute toxicity tests revealed that rats treated with elevated doses of the extract showed no signs of toxicity. The extract induced reduction in total body mass and the white adipose tissue depots. The obese rats treated with the extract showed an increased fluid intake and feces excretion while their serum total cholesterol and triglyceride levels decreased compared to those in the controls, without any hematological changes. Taken together, the results showed that the constituents of J. decurrens extracts included phenolic compounds and exhibited antiobesity effects with no toxicity.
APA, Harvard, Vancouver, ISO, and other styles
8

Wilson, Carol. "CB1R inverse agonists—antiobesity effects without the neuropsychiatric adverse effects?" Nature Reviews Endocrinology 8, no. 10 (August 14, 2012): 564. http://dx.doi.org/10.1038/nrendo.2012.145.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Chuah, Li Oon, Wan Yong Ho, Boon Kee Beh, and Swee Keong Yeap. "Updates on Antiobesity Effect ofGarciniaOrigin (−)-HCA." Evidence-Based Complementary and Alternative Medicine 2013 (2013): 1–17. http://dx.doi.org/10.1155/2013/751658.

Full text
Abstract:
Garciniais a plant under the family of Clusiaceae that is commonly used as a flavouring agent. Various phytochemicals including flavonoids and organic acid have been identified in this plant. Among all types of organic acids, hydroxycitric acid or more specifically (−)-hydroxycitric acid has been identified as a potential supplement for weight management and as antiobesity agent. Variousin vivostudies have contributed to the understanding of the anti-obesity effects ofGarcinia/hydroxycitric acid via regulation of serotonin level and glucose uptake. Besides, it also helps to enhance fat oxidation while reducingde novolipogenesis. However, results from clinical studies showed both negative and positive antiobesity effects ofGarcinia/hydroxycitric acid. This review was prepared to summarise the update of chemical constituents, significance ofin vivo/clinical anti-obesity effects, and the importance of the current market potential ofGarcinia/hydroxycitric acid.
APA, Harvard, Vancouver, ISO, and other styles
10

Ito, Makoto, Sumiaki Fukuda, Shohei Sakata, Hisayo Morinaga, and Takeshi Ohta. "Pharmacological Effects of JTT-551, a Novel Protein Tyrosine Phosphatase 1B Inhibitor, in Diet-Induced Obesity Mice." Journal of Diabetes Research 2014 (2014): 1–7. http://dx.doi.org/10.1155/2014/680348.

Full text
Abstract:
Protein tyrosine phosphatase 1B (PTP1B) is a negative regulator of leptin signaling as well as insulin signaling. JTT-551 is a new PTP1B inhibitor, which is reported to improve glucose metabolism by enhancement of insulin signaling. We have evaluated an antiobesity effect of JTT-551 using diet-induced obesity (DIO) mice. A single administration of JTT-551 was provided to DIO mice with or without leptin, and DIO mice were given food containing JTT-551 for six weeks. A single administration of JTT-551 with leptin treatment enhanced the food inhibition and the signal transducer and activator of transcription 3 (STAT3) phosphorylation in hypothalamus. Moreover, chronic administration of JTT-551 showed an antiobesity effect and an improvement of glucose and lipid metabolism in DIO mice. JTT-551 shows an antiobesity effect possibly by enhancement of leptin signaling and could be useful in the treatment of type 2 diabetes and obesity.
APA, Harvard, Vancouver, ISO, and other styles
11

Kwan, Hiu Yee, Xiaojuan Chao, Tao Su, Xiuqiong Fu, Anfernee Kai Wing Tse, Wang fun Fong, and Zhi-Ling Yu. "The anticancer and antiobesity effects of Mediterranean diet." Critical Reviews in Food Science and Nutrition 57, no. 1 (April 2015): 82–94. http://dx.doi.org/10.1080/10408398.2013.852510.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Nathan, Pradeep J., Barry V. O’Neill, Antonella Napolitano, and Edward T. Bullmore. "Neuropsychiatric Adverse Effects of Centrally Acting Antiobesity Drugs." CNS Neuroscience & Therapeutics 17, no. 5 (July 7, 2010): 490–505. http://dx.doi.org/10.1111/j.1755-5949.2010.00172.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Fernández-Quintela, Alfredo, Iñaki Milton-Laskibar, Marcela González, and Maria P. Portillo. "Antiobesity effects of resveratrol: which tissues are involved?" Annals of the New York Academy of Sciences 1403, no. 1 (August 10, 2017): 118–31. http://dx.doi.org/10.1111/nyas.13413.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Lee, In-Seung, Ki-Suk Kim, Kang-Hoon Kim, Jiyoung Park, Hyeon-soo Jeong, Yumi Kim, Yun-Cheol Na, et al. "Antihyperglycemic and Antiobesity Effects of JAL2 ondb/dbMice." Evidence-Based Complementary and Alternative Medicine 2016 (2016): 1–10. http://dx.doi.org/10.1155/2016/6828514.

Full text
Abstract:
Lonicera japonicaThunb. (LJT) andRehmannia glutinosaLibosch. (RGL) have been used traditionally as a herbal medicine in Korean medicine. Using LC/Q-TOF was performed to profile the two herbal medicines and the mixture of LJR and RGL (JAL2, ratio 1 : 1). We performed oral glucose tolerance test (OGTT) and plasma GLP-1 and insulin secretion by multiplex assays to investigate antidiabetic effects of LJT, RGL, and JAL2 indb/dbmice, the mice model of type 2 diabetes mellitus (T2DM). Also, the antiobesity-related factors such as plasma peptide YY (PYY), triglyceride, total cholesterol, HDL, LDL, and weight of liver, epididymal, and retroperitoneal fat tissue were investigated. Through the multiplex assay, it was found that JAL2 treatment more efficiently attenuated high levels of blood glucose by stimulating GLP-1 secretion and reduced LDL concentration and weight of liver and retroperitoneal fat tissue compared to LJT or RGL treated separately. These results suggest that the JAL2 has antidiabetes and antiobesity effects in T2DM mice model.
APA, Harvard, Vancouver, ISO, and other styles
15

Moriyasu, Yuuki, Chiho Fukumoto, Maki Wada, Erika Yano, Hiroshi Murase, Masatoshi Mizuno, Nobuhiro Zaima, and Tatsuya Moriyama. "Validation of Antiobesity Effects of Black Soybean Seed Coat Powder Suitable as a Food Material: Comparisons with Conventional Yellow Soybean Seed Coat Powder." Foods 10, no. 4 (April 13, 2021): 841. http://dx.doi.org/10.3390/foods10040841.

Full text
Abstract:
In this study, we fed obese model mice black soybean seed coat powder (BSCP) and evaluated the antiobesity effects. As a control, normal yellow soybean seed coat powder (YSCP) was used. C57BL/6J, a high-fat diet-induced obesity model mouse, was fed a high-fat diet containing BSCP or YSCP (20% fat) to induce obesity. The results showed that in the BSCP group, it caused significant suppression of body weight gain and suppression of white adipose tissue weight compared with the YSCP group. Moreover, it significantly decreased serum leptin levels, which correlated with visceral fat mass, and increased antidiabetic adipocytokine and adiponectin levels. Therefore, this suggests the pigmented components contained in BSCP have an antiobesity effect in obese model mice. It is suggested that this material, which can be prepared without extraction with an organic solvent and is suitable for use as a food material, could be a functional food material with a practicable antiobesity effect.
APA, Harvard, Vancouver, ISO, and other styles
16

Gooda Sahib, Najla, Nazamid Saari, Amin Ismail, Alfi Khatib, Fawzi Mahomoodally, and Azizah Abdul Hamid. "Plants' Metabolites as Potential Antiobesity Agents." Scientific World Journal 2012 (2012): 1–8. http://dx.doi.org/10.1100/2012/436039.

Full text
Abstract:
Obesity and obesity-related complications are on the increase both in the developed and developing world. Since existing pharmaceuticals fail to come up with long-term solutions to address this issue, there is an ever-pressing need to find and develop new drugs and alternatives. Natural products, particularly medicinal plants, are believed to harbor potential antiobesity agents that can act through various mechanisms either by preventing weight gain or promoting weight loss amongst others. The inhibition of key lipid and carbohydrate hydrolyzing and metabolizing enzymes, disruption of adipogenesis, and modulation of its factors or appetite suppression are some of the plethora of targeted approaches to probe the antiobesity potential of medicinal plants. A new technology such as metabolomics, which deals with the study of the whole metabolome, has been identified to be a promising technique to probe the progression of diseases, elucidate their pathologies, and assess the effects of natural health products on certain pathological conditions. This has been applied to drug research, bone health, and to a limited extent to obesity research. This paper thus endeavors to give an overview of those plants, which have been reported to have antiobesity effects and highlight the potential and relevance of metabolomics in obesity research.
APA, Harvard, Vancouver, ISO, and other styles
17

Ikebe, Emi, Nichole Fife-Koshinomi, Takashi Matsumoto, Takaaki Yahiro, Taichi Ikebe, and Hidekatsu Iha. "Antiobesity and Anti-Inflammatory Effects of Orally Administered Bonito Extracts on Mice Fed a High-Fat Diet." Evidence-Based Complementary and Alternative Medicine 2017 (2017): 1–13. http://dx.doi.org/10.1155/2017/9187167.

Full text
Abstract:
Background. The condensed fermentative extract of bonito (BoE), skipjack tuna (Katsuwonus pelamis), has claimed its health conditioning effects against lifestyle-related diseases such as hypertension and type 2 diabetes. Methods. We evaluated the antiobesity and anti-inflammatory effects of BoE on mice fed a high-fat diet (HFD). Mice (9 weeks of age) were maintained for 11 weeks on HFD with or without BoE (50 mg or 500 mg/kg). Results. Compared with untreated mice, BoE50 or BoE500 mice achieved maximum weight reductions of 7.4% (males) and 11.4% (females), and visceral fat in male BoE500 mice was more decreased among all mice (P = 0.00459). Furthermore, an antiobesity gene uncoupling protein-1 was significantly induced in the visceral fat tissues of male BoE500 (P = 0.0110) and female BoE50 and BoE500 mice (P = 0.0110 and P = 0.0110, resp.). Finally, we detected reduced amount of granulocyte-colony stimulating factor (P = 0.0250) in the sera of female BoE50 and interleukin- (IL-) 5 (P = 0.0120), IL-6 (P = 0.0118), and IL-13 (P = 0.0243) in female BoE500 mice. Conclusion. The antiobesity and anti-inflammatory effects of BoE were demonstrated with our examination system and any toxic adverse effects were not observed in mice during the 3-month investigation.
APA, Harvard, Vancouver, ISO, and other styles
18

Men, Tran Thanh, Duong Ngoc Van Thanh, Masamitsu Yamaguchi, Takayoshi Suzuki, Gen Hattori, Masayuki Arii, Nguyen Tien Huy, and Kaeko Kamei. "ADrosophilaModel for Screening Antiobesity Agents." BioMed Research International 2016 (2016): 1–10. http://dx.doi.org/10.1155/2016/6293163.

Full text
Abstract:
Although triacylglycerol, the major component for lipid storage, is essential for normal physiology, its excessive accumulation causes obesity in adipose tissue and is associated with organ dysfunction in nonadipose tissue. Here, we focused on theDrosophilamodel to develop therapeutics for preventing obesity. The brummer (bmm) gene inDrosophila melanogasteris known to be homologous with human adipocyte triglyceride lipase, which is related to the regulation of lipid storage. We established aDrosophilamodel for monitoringbmmexpression by introducing the green fluorescent protein (GFP) gene as a downstream reporter of thebmmpromoter. The third-instar larvae ofDrosophilashowed the GFP signal in all tissues observed and specifically in the salivary gland nucleus. To confirm the relationship betweenbmmexpression and obesity, the effect of oral administration of glucose diets onbmmpromoter activity was analyzed. TheDrosophilaflies given high-glucose diets showed higher lipid contents, indicating the obesity phenotype; this was suggested by a weaker intensity of the GFP signal as well as reducedbmmmRNA expression. These results demonstrated that the transgenicDrosophilamodel established in this study is useful for screening antiobesity agents. We also report the effects of oral administration of histone deacetylase inhibitors and some vegetables on thebmmpromoter activity.
APA, Harvard, Vancouver, ISO, and other styles
19

Min, Jiyoung, Jiwon Shinn, and Hun-Sung Kim. "Development of a predictive model for the side effects of liraglutide." Cardiovascular Prevention and Pharmacotherapy 4, no. 2 (April 30, 2022): 87–93. http://dx.doi.org/10.36011/cpp.2022.4.e12.

Full text
Abstract:
Background: Liraglutide, a drug used for the management of obesity, has many known side effects. In this study, we developed a predictive model for the occurrence of liraglutide-related side effects using data from electronic medical records (EMRs).Methods: This study included 237 patients from Seoul St. Mary's Hospital and Eunpyeong St. Mary's Hospital who were prescribed liraglutide. An endocrinologist obtained medical data through an EMR chart review. Model performance was evaluated using the mean of the area under the receiver operating characteristic curve (AUROC) with a 95% confidence interval (CI).Results: A predictive model was developed for patients who were prescribed liraglutide. However, 37.1% to 75.5% of many variables were missing, and the AUROC of the developed predictive model was 0.630 (95% CI, 0.551–0.708). Patients who had previously taken antiobesity medication had significantly fewer side effects than those without previous antiobesity medication use (20.7% vs. 41.4%, P<0.003). The risk of side effect occurrence was significantly higher in patients with diabetes than in patients without diabetes by 2.389 times (odds ratio, 2.389; 95% CI, 1.115–5.174).Conclusions: This study did not successfully develop a predictive model for liraglutide-related side effects, primarily due to issues related to missing data. When prescribing antiobesity drugs, detailed records and basic blood tests are expected to be essential. Further large-scale studies on liraglutide-related side effects are needed after obtaining high-quality data.
APA, Harvard, Vancouver, ISO, and other styles
20

Tziomalos, Konstantinos, Hariklia V. Dimitroula, Niki Katsiki, Christos Savopoulos, and Apostolos I. Hatzitolios. "Effects of Lifestyle Measures, Antiobesity Agents, and Bariatric Surgery on Serological Markers of Inflammation in Obese Patients." Mediators of Inflammation 2010 (2010): 1–14. http://dx.doi.org/10.1155/2010/364957.

Full text
Abstract:
Overweight and obesity are highly prevalent in developed countries and are also becoming more frequent in the developing world. Overweight and obese patients have elevated levels of several inflammatory markers and this inflammatory state might contribute to their increased vascular risk. We summarize the effects of lifestyle changes, antiobesity agents, and bariatric surgery on serological inflammatory markers in overweight and obese patients. Most studies showed a decrease in inflammation with all 3 interventions. However, it remains to be established whether the decrease in inflammatory markers induced by lifestyle changes or (where indicated) with antiobesity agents or bariatric surgery will translate into reduced vascular morbidity and mortality in overweight and obese patients.
APA, Harvard, Vancouver, ISO, and other styles
21

Xiong, Ye, Ling Shen, Kristina J. Liu, Patrick Tso, Yuqing Xiong, Guangji Wang, Stephen C. Woods, and Min Liu. "Antiobesity and Antihyperglycemic Effects of Ginsenoside Rb1 in Rats." Diabetes 59, no. 10 (August 3, 2010): 2505–12. http://dx.doi.org/10.2337/db10-0315.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Azzini, Elena, Jasminka Giacometti, and Gian Luigi Russo. "Antiobesity Effects of Anthocyanins in Preclinical and Clinical Studies." Oxidative Medicine and Cellular Longevity 2017 (2017): 1–11. http://dx.doi.org/10.1155/2017/2740364.

Full text
Abstract:
The natural phytochemicals present in foods, including anthocyanins, might play a role in attenuating obesity by producing a decrease in weight and adipose tissue. This review focused on current knowledge about anthocyanins’ role in obesity and its related comorbidities reported in animal models and humans. We summarized their target identification and mechanism of action through several pathways and their final effects on health and well-being. Into consideration of ongoing researches, we highlighted the following key points: a healthy relationship between anthocyanin supplementation and antiobesity effects suffers of the same pros and cons evidenced when the beneficial responses to other phytochemical treatments towards different degenerative diseases have been considered; the different dosage applied in animal versus clinical studies; the complex metabolism and biotransformation to which anthocyanins and phytochemicals are subjected in the intestine and tissues; the possibility that different components present in the supplemented mixtures can interact generating antagonistic, synergistic, or additive effects difficult to predict, and the difference between prevention and therapy. The evolution of the field must seriously consider the need to establish new and adequate cellular and animal models which may, in turn, allow the design of more efficient and prevention-targeted clinical studies.
APA, Harvard, Vancouver, ISO, and other styles
23

Malematja, R. O., V. P. Bagla, I. Njanje, V. Mbazima, K. W. Poopedi, L. Mampuru, and M. P. Mokgotho. "Potential Hypoglycaemic and Antiobesity Effects ofSenna italicaLeaf Acetone Extract." Evidence-Based Complementary and Alternative Medicine 2018 (2018): 1–10. http://dx.doi.org/10.1155/2018/5101656.

Full text
Abstract:
Background. Type II diabetes is on the rise while obesity is one of the strongest risk factors of type II diabetes. The search for a drug for type II that can equally mitigate obesity related complication is desired.Methods. The acetone leaf extract ofSenna italicawas evaluated for its cytotoxic, antiglycation, and lipolytic effect, glucose uptake, and GLUT4 translocation and expression using published methods, while that for adipogenesis and protein expression levels of obesity related adipokines was assessed using adipogenesis assay and mouse adipokine proteome profiler kit, respectively. The possible mechanism of glucose uptake was assessed through the inhibition of PI3K pathway.Results. The extract had no adverse effect on 3T3-L1 cell viability (CC50 > 1000 μg/ml). High antiglycation effect was attained at 10 mg/ml, while at 25–200 μg/ml it showed no significant increase in adipogenesis and lipolysis. The extract at 100 μg/ml was shown to decrease the expression levels of various adipokines and minimal glucose uptake at 50–100 μg/ml with a nonsignificant antagonistic effect when used in combination with insulin. GLUT4 translocation and expression were attained at 50–100 μg/ml with an increase in GLUT4 expression when in combination with insulin.Conclusion. The acetone leaf extract ofS. italicastimulates glucose uptake through the PI3K-dependent pathway and can serve as a source of therapeutic agent for the downregulation of obesity-associated adipokines in obesity and antiglycation agents.
APA, Harvard, Vancouver, ISO, and other styles
24

Ju, Jaehyun, Jia-Le Song, and Kun-Young Park. "Antiobesity Effects of Bamboo Salt in C57BL/6 Mice." Journal of Medicinal Food 18, no. 6 (June 2015): 706–10. http://dx.doi.org/10.1089/jmf.2014.3271.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Rains, Tia M., Sanjiv Agarwal, and Kevin C. Maki. "Antiobesity effects of green tea catechins: a mechanistic review." Journal of Nutritional Biochemistry 22, no. 1 (January 2011): 1–7. http://dx.doi.org/10.1016/j.jnutbio.2010.06.006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Cui, Meizi, Hee-Young Kim, Kyung Hee Lee, Ji-Kang Jeong, Ji-Hee Hwang, Kyu-Young Yeo, Byung-Hee Ryu, Jung-Ho Choi, and Kun-Young Park. "Antiobesity effects of kimchi in diet-induced obese mice." Journal of Ethnic Foods 2, no. 3 (September 2015): 137–44. http://dx.doi.org/10.1016/j.jef.2015.08.001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Liu, Peiyun, Wangting Zhou, Weiqi Xu, Yujia Peng, Yamei Yan, Lu Lu, Jia Mi, Xiaoxiong Zeng, and Youlong Cao. "The Main Anthocyanin Monomer from Lycium ruthenicum Murray Fruit Mediates Obesity via Modulating the Gut Microbiota and Improving the Intestinal Barrier." Foods 11, no. 1 (December 30, 2021): 98. http://dx.doi.org/10.3390/foods11010098.

Full text
Abstract:
Anthocyanins have been shown to exert certain antiobesity properties, but the specific relationship between anthocyanin-induced beneficial effects and the gut microbiota remains unclear. Petunidin-3-O-[rhamnopyranosyl-(trans-p-coumaroyl)]-5-O-(β-D-glucopyranoside) (P3G) is the main anthocyanin monomer from the fruit of Lycium ruthenicum Murray. Therefore, in this study, we investigated the antiobesity and remodeling effects of P3G on gut microbiota through a high-fat diet (HFD)-induced obesity mouse model and a fecal microbiota transplantation experiment. P3G was found to reduce body weight gain, fat accumulation, and liver steatosis in HFD-induced obese mice. Moreover, supplementation with P3G alleviated the HFD-induced imbalance in gut microbiota composition, and transferring the P3G-regulated gut microbiota to recipient mice provided comparable protection against obesity. This is the first time evidence is provided that P3G has an antiobesity effect by changing the intestinal microbiota. Our present data highlight a link between P3G intervention and enhancement in gut barrier integrity. This may be a promising option for obesity prevention.
APA, Harvard, Vancouver, ISO, and other styles
28

Han, Hee-Soo, Kyung-Sook Chung, Yu-Kyong Shin, Jae-Sik Yu, Seung-Hyun Kang, Sun-Hee Lee, and Kyung-Tae Lee. "Effect of Standardized Hydrangea serrata (Thunb.) Ser. Leaves Extract on Body Weight and Body Fat Reduction in Overweight or Obese Humans: A Randomized Double-Blind Placebo-Controlled Study." Nutrients 14, no. 1 (January 3, 2022): 208. http://dx.doi.org/10.3390/nu14010208.

Full text
Abstract:
Obesity is a major health problem that is caused by body fat accumulation and that can lead to metabolic diseases. Owing to several side effects of the currently used antiobesity drugs, natural plants have risen as safe and potential candidates to alleviate obesity. We have previously reported the antiobesity effect of Hydrangea serrata (Thunb.) Ser. leaves extract (WHS) and its underlying mechanisms. As an extension of our preclinical studies, this study aimed to investigate the effect of WHS on body weight and body fat reduction in overweight or obese humans. A total of 93 healthy overweight or obese males and females, aged 19–65 years, with body mass indexes (BMIs) ≥ 25 and <32 kg/m2, were recruited and received either an oral administration of 600 mg of WHS, or placebo tablets for 12 weeks. Daily supplementation with WHS decreased body weights, body fat masses, and BMIs compared with the placebo-treated group. The hip circumferences, visceral fat areas, abdominal fat areas, and visceral-to-subcutaneous ratios decreased after WHS supplementation. No significant side effects were observed during or after the 12 weeks of WHS intake. In conclusion, WHS, which has beneficial effects on body weight and body fat reduction, could be a promising antiobesity supplement that does not produce any side effects.
APA, Harvard, Vancouver, ISO, and other styles
29

Qowiyyah, Atun, Setiadi Ihsan, Hesti Renggana, and Maila Nisa Khoeriyah. "THE ANTIOBESITY ACTIVITY OF ETHANOL EXTRACT OF ROSE APPLE (Syzygium jambos (L.) Alston) ON FEMALE WISTAR RATS." Journal of Pharmacy Science and Technology 3, no. 1 (April 18, 2021): 135. http://dx.doi.org/10.30649/pst.v3i1.103.

Full text
Abstract:
<p>Obesity prevalence has increased in recent years and has caused serious health problems. This research was carried out to obtain alternative antiobesity therapy with more minimal side effects. Antiobesity activity of rose apple (Syzygium jambos (L.) Alston) leaves on female Wistar rats induced by high carbohydrate food for 45 days and subcutaneously injection of MSG 2 g/kgbw. Extraction was carried out using maceration method 96% ethanol. The test parameters observed were body weight, food intake, stool consistency and weight, liver and abdominal fat tissue weight. The results showed that high carbohydrate food and monosodium glutamate could induce obesity. Ethanol extract of rose apple leaves at doses of 25, 50 and 100 mg/kgbw body weight had antiobesity activity by inhibiting body weight gain significantly compased to positive control group (p&lt;0.05). The highest antiobesity effect was shown by the ethanol extract of rose apple leaves at a doses of 50 mg/kgbw with % inhibition of body weight gain of 169.3% to positive control group. Ethanol extract of rose apple leaves may reduce appetite, but didn’t have laxative effect and couldn’t reduce fat deposits in the liver and abdominal fat tissue.</p>
APA, Harvard, Vancouver, ISO, and other styles
30

Kamiya, Tomoyasu, Mayu Sameshima-Kamiya, Rika Nagamine, Masahito Tsubata, Motoya Ikeguchi, Kinya Takagaki, Tsutomu Shimada, and Masaki Aburada. "The Crude Extract fromPuerariaeFlower Exerts Antiobesity and Antifatty Liver Effects in High-Fat Diet-Induced Obese Mice." Evidence-Based Complementary and Alternative Medicine 2012 (2012): 1–6. http://dx.doi.org/10.1155/2012/272710.

Full text
Abstract:
Kudzu, a leguminous plant, has long been used in folk medicine. In particular, its flowers are used in Japanese and Chinese folk medicine for treating hangovers. We focused on the flower of Kudzu (Puerariae thomsonii), and we previously reported the antiobesity effect ofPuerariae thomsoniiflower extract (PFE) in humans. In this study, we conducted an animal study to investigate the effect of PFE on visceral fat and hepatic lipid levels in mice with diet-induced obesity. In addition, we focused on gene expression profiles to investigate the antiobesity mechanism of PFE. Male C57BL/6J mice were fed a high-fat diet (HFD) or an HFD supplemented with 5% PFE for 14 days. PFE supplementation significantly reduced body weight and white adipose tissue (WAT) weight. Moreover, in the histological analysis, PFE supplementation improved fatty liver. Hepatic reverse transcription-polymerase chain reaction revealed that PFE supplementation downregulated acetyl-CoA carboxylase expression. For adipose tissue, the expressions of hormone-sensitive lipase in WAT and uncoupling protein 1 in brown adipose tissue (BAT) were significantly upregulated. These results suggest that PFE exerts antiobesity and antifatty liver effects in high-fat diet-induced obese mice through suppressing lipogenesis in the liver, stimulating lipolysis in WAT, and promoting thermogenesis in BAT.
APA, Harvard, Vancouver, ISO, and other styles
31

Xiang, Lan, Qiaobei Wu, Lihong Cheng, Kaiyue Sun, Jing Li, Minoru Yoshida, and Jianhua Qi. "Leptin and Adiponectin Signaling Pathways Are Involved in the Antiobesity Effects of Peanut Skin Extract." Oxidative Medicine and Cellular Longevity 2019 (October 14, 2019): 1–14. http://dx.doi.org/10.1155/2019/2935315.

Full text
Abstract:
Excessive food intake and metabolic disorder promote obesity and diabetes. In China, peanut skin is used as a herbal medicine to treat hemophilia, thrombocytopenic purpura, and hepatic hemorrhage. In the present study, we demonstrated that peanut skin extract (PSE) safely reduced appetite, body weight, fat tissue, plasma TG and TC, and blood glucose level in mice with diet-induced obesity (DIO). Moreover, the leptin/leptin receptor/neuropeptide Y (NPY) and adiponectin signaling pathways involved in the antiobesity effects of PSE are confirmed through leptin and adiponectin overexpression and leptin receptor silencing in mice. PSE consisted of oligosaccharide and polyphenol in a mass ratio of 45 : 55, and both parts were important for the antiobesity function of PSE. Our results suggested that PSE can be developed as functional medical food to treat metabolic disorders and obesity.
APA, Harvard, Vancouver, ISO, and other styles
32

Hwang, Deunsol, Jong-Beom Seo, Hun-Young Park, Jisu Kim, and Kiwon Lim. "Capsiate Intake with Exercise Training Additively Reduces Fat Deposition in Mice on a High-Fat Diet, but Not without Exercise Training." International Journal of Molecular Sciences 22, no. 2 (January 14, 2021): 769. http://dx.doi.org/10.3390/ijms22020769.

Full text
Abstract:
While exercise training (ET) is an efficient strategy to manage obesity, it is recommended with a dietary plan to maximize the antiobesity functions owing to a compensational increase in energy intake. Capsiate is a notable bioactive compound for managing obesity owing to its capacity to increase energy expenditure. We aimed to examine whether the antiobesity effects of ET can be further enhanced by capsiate intake (CI) and determine its effects on resting energy expenditure and metabolic molecules. Mice were randomly divided into four groups (n = 8 per group) and fed high-fat diet. Mild-intensity treadmill ET was conducted five times/week; capsiate (10 mg/kg) was orally administered daily. After 8 weeks, resting metabolic rate and metabolic molecules were analyzed. ET with CI additively reduced the abdominal fat rate by 18% and solely upregulated beta-3-adrenoceptors in adipose tissue (p = 0.013) but did not affect the metabolic molecules in skeletal muscles. Surprisingly, CI without ET significantly increased the abdominal fat rate (p = 0.001) and reduced energy expenditure by 9%. Therefore, capsiate could be a candidate compound for maximizing the antiobesity effects of ET by upregulating beta-3-adrenoceptors in adipose tissue, but CI without ET may not be beneficial in managing obesity.
APA, Harvard, Vancouver, ISO, and other styles
33

Romano, Adele, Roberto Coccurello, Giacomo Giacovazzo, Gaurav Bedse, Anna Moles, and Silvana Gaetani. "Oleoylethanolamide: A Novel Potential Pharmacological Alternative to Cannabinoid Antagonists for the Control of Appetite." BioMed Research International 2014 (2014): 1–10. http://dx.doi.org/10.1155/2014/203425.

Full text
Abstract:
The initial pharmaceutical interest for the endocannabinoid system as a target for antiobesity therapies has been restricted by the severe adverse effects of the CB1 antagonist rimonabant. This study points at oleoylethanolamide (OEA), a monounsaturated analogue, and functional antagonist of anandamide, as a potential and safer antiobesity alternative to CB1 antagonism. Mice treated with equal doses (5 or 10 mg/kg, i.p.) of OEA or rimonabant were analyzed for the progressive expression of spontaneous behaviors (eating, grooming, rearing, locomotion, and resting) occurring during the development of satiety, according to the paradigm called behavioral satiety sequence (BSS). Both drugs reduced food (wet mash) intake to a similar extent. OEA treatment decreased eating activity within the first 30 min and caused a temporary increase of resting time that was not accompanied by any decline of horizontal, vertical and total motor activity. Besides decreasing eating activity, rimonabant caused a marked increase of the time spent grooming and decreased horizontal motor activity, alterations that might be indicative of aversive nonmotivational effects on feeding. These results support the idea that OEA suppresses appetite by stimulating satiety and that its profile of action might be predictive of safer effects in humans as a novel antiobesity treatment.
APA, Harvard, Vancouver, ISO, and other styles
34

Xu, Guangyuan, Hisae Yoshitomi, Wen Sun, Xuan Guo, Lili Wu, Xiangyu Guo, Lingling Qin, et al. "Cyclocarya paliurus (Batal.) Ijinskaja Aqueous Extract (CPAE) Ameliorates Obesity by Improving Insulin Signaling in the Hypothalamus of a Metabolic Syndrome Rat Model." Evidence-Based Complementary and Alternative Medicine 2017 (2017): 1–9. http://dx.doi.org/10.1155/2017/4602153.

Full text
Abstract:
Background. Antiobesity drugs may not be optimal for treating obesity. However novel antiobesity agents, especially those derived from natural products, may be suitable. Therefore, we investigated the effects and mechanisms of Cyclocarya paliurus (CP) aqueous extract (CPAE) on obesity. Methods. SHR.Cg-Leprcp/NDmcr (SHR/cp) rats were used as a model of obesity and metabolic syndrome. Experimental animals were allocated into two groups—control and CPAE (0.5 g/kg)—for a 7-week treatment period. Examinations were performed, including general physiological characteristics, obesity-related biochemical parameters, and insulin-signaling pathway-related proteins in the hypothalamus. Results. Treatment with CPAE reduced food intake, body weight, organ weight, fat mass, and body mass index (BMI) in SHR/cp rats. Meanwhile, CPAE also decreased the levels of fasting serum glucose, fasting serum insulin, HOMA-IR, serum free fatty acids, serum malondialdehyde, serum superoxide dismutase, and serum total-glutathione. The levels of phosphorylation of target proteins—including InsR, IRS1, PI3Kp85, Akt, and FoXO1 as well as protein expression of POMC—were significantly upregulated in the hypothalamus, but NPY expression remarkably decreased. Conclusions. CPAE has antiobesity, antihypoglycemic, antihypolipidemic, and antioxidant properties. The mechanism responsible for the antiobesity effect of CPAE may be related to suppression of energy intake via regulation of insulin-signaling pathway in the hypothalamus.
APA, Harvard, Vancouver, ISO, and other styles
35

Rani, Neerja, Surendra Kumar Sharma, and Neeru Vasudeva. "Assessment of Antiobesity Potential ofAchyranthes asperaLinn. Seed." Evidence-Based Complementary and Alternative Medicine 2012 (2012): 1–7. http://dx.doi.org/10.1155/2012/715912.

Full text
Abstract:
The present study was designed to evaluate the quality control parameters, quantitative phytochemical analysis (total phenols, total flavonoids, and total saponin content), and the antiobesity effect of ethanol extract ofAchyranthes asperaLinn. seed (EAA) by employingin vitroandin vivomodels. Inin vitrostudy, the inhibitory activity of EAA on pancreatic amylase and lipase was measured. Thein vivopancreatic lipase activity was evaluated by measurement of plasma triacylglycerol levels after oral administration of EAA along with lipid emulsion to Swiss albino mice. The EAA inhibited pancreatic amylase and lipase activity in vitro and elevations of plasma triacylglycerol level in mice. Furthermore, the antiobesity effect of EAA (900 mg/kg) was assessed in mice fed a high-fat diet with or without EAA for 6 weeks. EAA significantly suppressed the increase in body,retroperitoneal adiposetissue, liver weights, and serum parameters, namely; total cholesterol, total triglyceride, and LDL-cholesterol level. The anti obesity effects of EAA in high-fat-diet-treated mice may be partly mediated through delaying the intestinal absorption of dietary fat by inhibiting pancreatic amylase and lipase activity. Histopathological effects of EAA on the liver of mice were also assessed.
APA, Harvard, Vancouver, ISO, and other styles
36

FENG, XUDONG. "307-LB: IL1R1 Mediates Celastrol’s Leptin-Sensitization and Antiobesity Effects." Diabetes 68, Supplement 1 (June 2019): 307—LB. http://dx.doi.org/10.2337/db19-307-lb.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Yao, Yuan, and Long Ma. "Is IL1R1 required for celastrol’s leptin-sensitization and antiobesity effects?" Traditional Medicine Research 4, no. 4 (2019): 174–77. http://dx.doi.org/10.53388/tmr20190415116.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Ukwuani, A. N., M. G. Abukakar, R. A. Shehu, and L. G. Hassan. "Antiobesity Effects of Pulp Extract Tamarindus indica in Albino Rat." Asian Journal of Biochemistry 3, no. 4 (June 15, 2008): 221–27. http://dx.doi.org/10.3923/ajb.2008.221.227.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

Jeon, Seon-Min, Seung-A. Lee, and Myung-Sook Choi. "Antiobesity and Vasoprotective Effects of Resveratrol in ApoE-Deficient Mice." Journal of Medicinal Food 17, no. 3 (March 2014): 310–16. http://dx.doi.org/10.1089/jmf.2013.2885.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Bhattarai, Bharat Raj, Bhooshan Kafle, Ji-Sun Hwang, Deegendra Khadka, Sun-Myung Lee, Jae-Seung Kang, Seung Wook Ham, Inn-Oc Han, Hwangseo Park, and Hyeongjin Cho. "Thiazolidinedione derivatives as PTP1B inhibitors with antihyperglycemic and antiobesity effects." Bioorganic & Medicinal Chemistry Letters 19, no. 21 (November 2009): 6161–65. http://dx.doi.org/10.1016/j.bmcl.2009.09.020.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Okada, Tomoko, Yasuyuki Mizuno, Shinichi Sibayama, Masashi Hosokawa, and Kazuo Miyashita. "Antiobesity Effects of Undaria Lipid Capsules Prepared with Scallop Phospholipids." Journal of Food Science 76, no. 1 (November 4, 2010): H2—H6. http://dx.doi.org/10.1111/j.1750-3841.2010.01878.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Feng, Xudong, Dongxian Guan, Thomas Auen, Jae Won Choi, Mario Andrés Salazar Hernández, Jaemin Lee, Hyonho Chun, et al. "IL1R1 is required for celastrol’s leptin-sensitization and antiobesity effects." Nature Medicine 25, no. 4 (March 4, 2019): 575–82. http://dx.doi.org/10.1038/s41591-019-0358-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

Guo, Yu, Wei Fu, Yakai Xin, Jinlei Bai, Huifang Peng, Liujun Fu, Jie Liu, Liping Li, Yujin Ma, and Hongwei Jiang. "Antidiabetic and Antiobesity Effects of Artemether in db/db Mice." BioMed Research International 2018 (2018): 1–9. http://dx.doi.org/10.1155/2018/8639523.

Full text
Abstract:
This study is designed to investigate the effect of artemether on type 2 diabetic db/db mice. The experiments consisted of three groups: normal control (NC, db/+, 1% methylcellulose, intragastric administration), diabetic control (DM, db/db, 1% methylcellulose, intragastric administration), and artemether treated (artemether, db/db, 200 mg/kg of artemether, intragastric administration). The treatment lasted for two weeks. The food intake, body weight, and fasting blood glucose of mice were measured every three days. At the start and end of the experiment, the intraperitoneal glucose tolerance test (IPGTT) and insulin tolerance test (IPITT) were performed. We determined the serum insulin and glucagon levels by ELISA kits and calculated insulin resistance index (HOME-IR). HE staining was used to observe the morphologies of pancreas and liver in mice. The damage of pancreatic beta cells was evaluated by TUNEL staining and immunofluorescence. We found the following: (1) compared with the DM group, the food intake and weight increase rate of artemether group significantly reduced (P<0.05); (2) compared with pretreatment, artemether significantly reduced the fasting blood glucose levels, and the areas under the curves (AUCs) of IPGTT were decreased significantly, increasing the tolerance to glucose of db/db mice. (P<0.05); (3) artemether improved hyperinsulinemia and decreased the AUCs of IPITT and HOME-IR, increasing the insulin sensitivity of db/db mice. (4) Artemether significantly ameliorated islet vacuolar degeneration and hepatic steatosis in db/db mice. (5) Artemether reduced the apoptosis of pancreatic beta cells and increased insulin secretion in db/db mice compared with DM group (P<0.05). Our results indicated that artemether significantly improved glucose homeostasis and insulin resistance and had the potential activity to prevent obesity, reduced the severity of fatty liver, and protected pancreatic beta cells, promising to treat type 2 diabetes.
APA, Harvard, Vancouver, ISO, and other styles
44

Meggyesy, Peter M., Shashank Masaldan, Sharnel A. S. Clatworthy, Irene Volitakis, Daniel J. Eyckens, Kathryn Aston-Mourney, and Michael A. Cater. "Copper Ionophores as Novel Antiobesity Therapeutics." Molecules 25, no. 21 (October 27, 2020): 4957. http://dx.doi.org/10.3390/molecules25214957.

Full text
Abstract:
The therapeutic utility of the copper ionophore disulfiram was investigated in a diet-induced obesity mouse model (C57BL/6J background), both through administration in feed (0.05 to 1% (w/w)) and via oral gavage (150 mg/kg) for up to eight weeks. Mice were monitored for body weight, fat deposition (perigonadal fat pads), metabolic changes (e.g., glucose dyshomeostasis) and pathologies (e.g., hepatic steatosis, hyperglycaemia and hypertriglyceridemia) associated with a high-fat diet. Metal-related pharmacological effects across major organs and serums were investigated using inductively coupled plasma mass spectrometry (ICP-MS). Disulfiram treatments (all modes) augmented hepatic copper in mice, markedly moderated body weight and abolished the deleterious systemic changes associated with a high-fat diet. Likewise, another chemically distinct copper ionophore H2(gtsm), administered daily (oral gavage), also augmented hepatic copper and moderated mouse body weight. Postmortem histological examinations of the liver and other major organs, together with serum aminotransferases, supported the reported therapeutic safety of disulfiram. Disulfiram specifically altered systemic copper in mice and altered hepatic copper metabolism, perturbing the incorporation of copper into ceruloplasmin (holo-ceruloplasmin biosynthesis) and subsequently reducing serum copper concentrations. Serum ceruloplasmin represents a biomarker for disulfiram activity. Our results establish copper ionophores as a potential class of antiobesity agents.
APA, Harvard, Vancouver, ISO, and other styles
45

Yoo, Sae-Rom, Mee-young Lee, Byoung-Kab Kang, Hyeun-Kyoo Shin, and Soo-Jin Jeong. "Soshiho-Tang Aqueous Extract Exerts Antiobesity Effects in High Fat Diet-Fed Mice and Inhibits Adipogenesis in 3T3-L1 Adipocytes." Evidence-Based Complementary and Alternative Medicine 2016 (2016): 1–9. http://dx.doi.org/10.1155/2016/2628901.

Full text
Abstract:
Soshiho-tang (SST; sho-saiko-to in Japanese; xiaochaihu-tang in Chinese) has generally been used to improve liver fibrosis- and cirrhosis-related symptoms in traditional Korean medicine. Although many studies have investigated the pharmacological properties of SST, its antiobesity effect has not been elucidated. Thus, our present study was carried out to evaluate the antiobesity effect of SST using a high fat diet- (HFD) induced obese mouse model and 3T3-L1 adipose cells. C57BL/6J mice were randomly divided into four groups (n=6/group), normal diet (ND), HFD-fed group, and HFD- and SST-fed groups (S200: 200 mg/kg of SST; S600: 600 mg/kg of SST) and given HFD with or without SST extract for 8 weeks. 3T3-L1 preadipocytes were differentiated into adipocytes for 8 days with or without SST. In the HFD-fed obese mice, body weight and fat accumulation in adipose tissue were significantly reduced by SST administration. Compared with control-differentiated adipocytes, SST significantly inhibited lipid accumulation by decreasing the triglyceride (TG) content and leptin concentration in 3T3-L1 adipocytes. SST also decreased the expression of adipogenesis-related genes including lipoprotein lipase (LPL), fatty acid binding protein 4 (FABP4), CCAAT/enhancer-binding protein-alpha (C/EBP-α), and peroxisome proliferator-activated receptor-gamma (PPAR-γ). Our findings suggest that SST has potential as a nontoxic antiobesity medication.
APA, Harvard, Vancouver, ISO, and other styles
46

Lyu, Xiaorui, Taibiao Lyu, Xue Wang, Huijuan Zhu, Hui Pan, Linjie Wang, Hongbo Yang, and Fengying Gong. "The Antiobesity Effect of GLP-1 Receptor Agonists Alone or in Combination with Metformin in Overweight /Obese Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis." International Journal of Endocrinology 2021 (February 13, 2021): 1–11. http://dx.doi.org/10.1155/2021/6616693.

Full text
Abstract:
Objectives. Both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and metformin (MET) have markedly antiobesity effects in overweight/obese polycystic ovary syndrome (PCOS) patients. However, there was no literature to compare the antiobesity effects of these two medicines. Therefore, a systematic review and meta-analysis were conducted in our present study to evaluate the antiobesity effects of GLP-1RAs either as monotherapy or combined with MET in comparison with MET alone in overweight/obese PCOS patients. Methods. All randomized controlled trials (RCTs) which reported the efficacy of GLP-1RAs and MET in overweight/obese PCOS patients in Medline (from Pubmed), Embase, Cochrane Central Register of Controlled Trials, Web of Science, and Scopus databases were independently searched by two reviewers. The random-effect model was used to pool data extracted from the included literature. The weighted mean difference (WMD) and 95% confidence interval (CI) were used to present the meta-analysis results (PROSPERO registration number: CRD42020173199). Results. A total of eight eligible RCTs were finally enrolled in our meta-analysis from the 587 retrieved literature. The results showed that GLP-1RAs alone or combined with MET was associated with a greater weight loss (N = 318, WMD = −2.61, 95% CI: −3.51 to −1.72, P ≤ 0.001 , I2 = 77.5%), more obvious reduction of waist circumference (N = 276, WMD = −3.46, 95% CI: −4.36 to −2.56, P ≤ 0.001 , I2 = 0.0%), and body mass index (BMI) (N = 318, WMD = −0.93, 95% CI: −1.60 to −0.26, P = 0.007 , I2 = 84.9%) in overweight/obese PCOS patients when compared with MET alone. Further sensitivity analysis demonstrated that the meta-analysis results of the efficacy differences in terms of body weight, waist circumference, and BMI were relatively stable and reliable. Conclusion. Our meta-analysis demonstrated that the antiobesity effect of GLP-1RAs alone or combined with MET was superior to MET alone in terms of weight loss, the reduction of waist circumference, and BMI. More large-scale, high-quality RCTs are needed to further confirm these results in PCOS patients.
APA, Harvard, Vancouver, ISO, and other styles
47

Li, Qian, Yuxiao Zou, and Sentai Liao. "Mulberry Leaf Polyphenols and Fiber Induce Synergistic Antiobesity and Display a Modulation Effect on Gut Microbiota and Metabolites." Current Developments in Nutrition 4, Supplement_2 (May 29, 2020): 1654. http://dx.doi.org/10.1093/cdn/nzaa063_052.

Full text
Abstract:
Abstract Objectives In this study we compared the antiobesity effects of mulberry leaf powder, dietary fiber, polyphenols, and a fiber/polyphenols mixture.Combining intestinal community modulation and metabolite analysis, we investigated the antiobesity effects and mechanisms of mulberry leaf components, detecting the interaction between mulberry leaf dietary fiber and polyphenol. Methods An obesity model was established by feeding rats with a high-calorie diet. Rats were divided into seven groups: the obesity model control (MC), positive control (PC), mulberry leaf powder (MLP), mulberry leaf fiber (MLF), mulberry leaf polyphenols (MLPS), mulberry leaf fiber and polyphenols mixture (MLM), and normal control (NC), and fed daily for 6 consecutive weeks.the 16S rRNA gene was sequenced using Illumina MiSeq.UPLC Triple TOF MS/MS system and Agilent 6890 N GC-MS were used to profile the urinary/fecal metabolites. Results The synergistic interaction between mulberry dietary fiber and polyphenols (MLM) in antiobesity was reported for the first time. The content of Firmicutes in the MC group was increased significantly. Except for the MLPS group, other test groups regulated the Firmicutes content to a normal level. Our study demonstrated that different components of mulberry leaves might achieve weight loss by reducing the amount of Lachnespiraceae. At the same time, the reduction Lactobacillus_vaginalis and Lactobacillus_gasseri species was closely related to the improvement of lipid metabolism profiles. In addition, the high energy diet induced feces and urine metabolic disorders in MC group with significant difference. The amino acid and oligopeptide metabolites were regulated to the NC level under the regulation of mulberry leaf components. Conclusions MLM group had the best efficiency on weight loss, indicating synergistic interactions between MLPS and MLF. The reduction of Firmicutes abundance, and the downstream Clostridiales, Lachnespiraceae, was a key pathway for the antiobesity effects. The increased abundances of Lactobacillus vaginalis and Lactobacillus gasseri might result in lipid metabolism disorder. The test groups regulated the amino acid and oligopeptides metabolic disorder tents to normal levels compared with the MC and NC groups. Funding Sources The Science & Technology Projects of Guangdong Province No.2017A050501022/No.2017A030310416.
APA, Harvard, Vancouver, ISO, and other styles
48

Park, Yong-Hyun, Jae-Joon Lee, Hee-Kyoung Son, Bok-Hee Kim, Jaemin Byun, and Jung-Heun Ha. "Antiobesity Effects of Extract from Spergularia marina Griseb in Adipocytes and High-Fat Diet-Induced Obese Rats." Nutrients 12, no. 2 (January 27, 2020): 336. http://dx.doi.org/10.3390/nu12020336.

Full text
Abstract:
Obesity has recently risen and become a serious health concern in Korea according to the westernized diet and altered lifestyle. Hence, there is a growing interest in the supplementation of phytochemicals to find a safe and effective functional ingredient to treat obesity. Spergularia marina Griseb (SM) has traditionally been used as a natural herb against chronic diseases in Korea. In this study, we investigated the antiobesity effects of SM in vitro and in vivo. SM ethanol extract (SME) inhibited proliferation and differentiation in murine adipocytes and primary porcine pre-adipocytes in a dose-dependent manner. In the in vivo study, supplementation of SM powder (SMP) remarkably attenuated fat accumulation in HFD-induced obese rats. In addition, SMP supplementation improved lipid profiles in the serum and tissues of high-fat induced obese rats. Collectively, these data indicated that SME exhibited antiobesity effects by modulating adipogenesis and lipolysis. Furthermore, SMP could be developed as an obesity-induced metabolic syndrome treatment.
APA, Harvard, Vancouver, ISO, and other styles
49

Park, Seon-Joo, Miey Park, Anshul Sharma, Kihyun Kim, and Hae-Jeung Lee. "Black Ginseng and Ginsenoside Rb1 Promote Browning by Inducing UCP1 Expression in 3T3-L1 and Primary White Adipocytes." Nutrients 11, no. 11 (November 12, 2019): 2747. http://dx.doi.org/10.3390/nu11112747.

Full text
Abstract:
In this study, we investigated the effects of black ginseng (BG) and ginsenoside Rb1, which induced browning effects in 3T3-L1 and primary white adipocytes (PWATs) isolated from C57BL/6 mice. BG and Rb1 suppressed the expressions of CCAAT/enhancer-binding protein alpha (C/EBPα) and sterol regulatory element-binding transcription factor-1c (SREBP-1c), whereas the expression level of peroxisome proliferator-activated receptor gamma (PPARγ) was increased. Furthermore, BG and Rb1 enhanced the protein expressions of the brown-adipocyte-specific markers PR domain containing 16 (PRDM16), peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α), and uncoupling protein 1 (UCP1). These results were further supported by immunofluorescence images of mitochondrial biogenesis. In addition, BG and Rb1 induced expressions of brown-adipocyte-specific marker proteins by AMP-activated protein kinase (AMPK) activation. BG and Rb1 exert antiobesity effects by inducing browning in 3T3-L1 cells and PWATs through AMPK-mediated pathway activation. We suggest that BG and Rb1 act as potential functional antiobesity food agents.
APA, Harvard, Vancouver, ISO, and other styles
50

Katsiki, Niki, Georgios A. Christou, and Dimitrios N. Kiortsis. "Editorial: Liraglutide and Cardiometabolic Effects: More than Just Another Antiobesity Drug?" Current Vascular Pharmacology 14, no. 1 (November 26, 2015): 76–79. http://dx.doi.org/10.2174/157016111401151126161741.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography